Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry)

American Journal of Cardiology

Volumn 107, Issue 4, 2011, Pages 528-534

  Claessen, Bimmer E ^a,b   Mehran, Roxana ^a,c   Leon, Martin B ^a,d   Heller, Eric A ^a,d   Weisz, Giora ^a,d   Syros, George ^a,d   Mintz, Gary S ^a,d   Franklin Bond, Theresa ^a,d   Apostolidou, Irene ^a,d   Henriques, Jose P S ^b   Stone, Gregg W ^a,d   Moses, Jeffrey W ^a,d   Dangas, George D ^a,c  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SIROLIMUS; TREATMENT OUTCOME;

EID: 79551683420     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.10.010     Document Type: Article

References (35)

1. M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, H.E. Ban, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, F. Molnar, and R. Falotico A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780
2. J.W. Moses, M.B. Leon, J.J. Popma, P.J. Fitzgerald, D.R. Holmes, C. OShaughnessy, R.P. Caputo, D.J. Kereiakes, D.O. Williams, P.S. Teirstein, J.L. Jaeger, and R.E. Kuntz Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. A. Caixeta, M.B. Leon, A.J. Lansky, E. Nikolsky, J. Aoki, J.W. Moses, J. Schofer, M.C. Morice, E. Schampaert, A.J. Kirtane, J.J. Popma, H. Parise, M. Fahy, and R. Mehran 5-Year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 2009 894 902
4. O.C. Marroquin, F. Selzer, S.R. Mulukutla, D.O. Williams, H.A. Vlachos, R.L. Wilensky, J.F. Tanguay, E.M. Holper, J.D. Abbott, J.S. Lee, C. Smith, W.D. Anderson, S.F. Kelsey, and K.E. Kip A comparison of bare-metal and drug-eluting stents for off-label indications N Engl J Med 358 2008 342 352
5. H.K. Win, A.E. Caldera, K. Maresh, J. Lopez, C.S. Rihal, M.A. Parikh, J.F. Granada, S. Marulkar, D. Nassif, D.J. Cohen, and N.S. Kleiman Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents JAMA 297 2007 2001 2009
6. T. Kimura, T. Morimoto, Y. Nakagawa, T. Tamura, K. Kadota, H. Yasumoto, H. Nishikawa, Y. Hiasa, T. Muramatsu, T. Meguro, N. Inoue, H. Honda, Y. Hayashi, S. Miyazaki, S. Oshima, T. Honda, N. Shiode, M. Namura, T. Sone, M. Nobuyoshi, T. Kita, and K. Mitsudo Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation Circulation 119 2009 987 995
7. J.M. Lasala, D.A. Cox, D. Dobies, K. Baran, W.B. Bachinsky, E.W. Rogers, J.A. Breall, D.H. Lewis, A. Song, R.M. Starzyk, S.R. Mascioli, K.D. Dawkins, and D.S. Baim Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries Circ Cardiovasc Interv 2 2009 285 293
8. J.W. van Werkum, A.A. Heestermans, A.C. Zomer, J.C. Kelder, M.J. Suttorp, B.J. Rensing, J.J. Koolen, B.R. Brueren, J.H. Dambrink, R.W. Hautvast, F.W. Verheugt, and J.M. ten Berg Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry J Am Coll Cardiol 53 2009 1399 1409
9. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, P.G. Steg, M.A. Morel, L. Mauri, P. Vranckx, E. McFadden, A. Lansky, M. Hamon, M.W. Krucoff, and P.W. Serruys Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
10. P.W. Serruys, S. Silber, S. Garg, R.J. van Geuns, G. Richardt, P.E. Buszman, H. Kelbaek, A.J. van Boven, S.H. Hofma, A. Linke, V. Klauss, W. Wijns, C. Macaya, P. Garot, C. Dimario, G. Manoharan, R. Kornowski, T. Ischinger, A. Bartorelli, J. Ronden, M. Bressers, P. Gobbens, M. Negoita, L.F. Van, and S. Windecker Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
11. E. Kedhi, K.S. Joesoef, E. McFadden, J. Wassing, M.C. Van, D. Goedhart, and P.C. Smits Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
12. A. Kaltoft, L.O. Jensen, M. Maeng, H.H. Tilsted, P. Thayssen, M. Bottcher, J.F. Lassen, L.R. Krusell, K. Rasmussen, K.N. Hansen, L. Pedersen, S.P. Johnsen, H.T. Sorensen, and L. Thuesen 2-Year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry) J Am Coll Cardiol 53 2009 658 664
13. V. Klauss, P.W. Serruys, G.A. van Es, P. Buszman, T. Ischinger, F. Eberli, R. Corti, W. Wijns, M.C. Morice, C. Di Mario, G. Schuler, A. Linke, P. Juni, and S. Windecker Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (leaders): a randomised non-inferiority trial: 24 months follow-up Am J Cardiol 104 2009 XVI
14. M.B. Leon, and D.E. Kandzari Two-year outcomes from the ENDEAVOR III trial: a randomized trial of the ENDEAVOR zotarolimus-eluting stent compared with the cypher sirolimus-eluting stent J Am Coll Cardiol 49 suppl 2007 45B
15. M.C. Morice, P. Serruys, C. Costantini, E. Wuelfert, W. Wijns, J. Fajadet, A. Columbo, G. Guagliumi, F. Molnar, E.B. Hayashi, J.E.M. Sousa, and M. Perin Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with de-novo native coronary artery lesions J Am Coll Cardiol 41 suppl 2003 32A
16. A.T. Ong, R.T. van Domburg, J. Aoki, K. Sonnenschein, P.A. Lemos, and P.W. Serruys Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry J Am Coll Cardiol 47 2006 1356 1360
17. P. Roy, L. de la Bonello, L.A. De, T. Okabe, T.L. Pinto Slottow, D.H. Steinberg, R. Torguson, K. Smith, Z. Xue, L.F. Satler, K.M. Kent, W.O. Suddath, A.D. Pichard, and R. Waksman Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry) Am J Cardiol 102 2008 292 297
18. E. Schampaert, J.W. Moses, J. Schofer, M. Schluter, A.H. Gershlick, E.A. Cohen, D.A. Palisaitis, G. Breithardt, D.J. Donohoe, H. Wang, J.J. Popma, R.E. Kuntz, and M.B. Leon Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and CSIRIUS with emphasis on late revascularizations and stent thromboses Am J Cardiol 98 2006 36 41
19. K. Rasmussen, M. Maeng, A. Kaltoft, P. Thayssen, H. Kelbaek, H.H. Tilsted, U. Abildgaard, E.H. Christiansen, T. Engstrom, L.R. Krusell, J. Ravkilde, P.R. Hansen, K.N. Hansen, S.Z. Abildstrom, J. Aaroe, J.S. Jensen, S.D. Kristensen, H.E. Botker, M. Madsen, S.P. Johnsen, L.O. Jensen, H.T. Sorensen, L. Thuesen, and J.F. Lassen Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
20. M. Billinger, J. Beutler, K.R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F.R. Eberli, T.F. Luscher, S. Wandel, P. Juni, B. Meier, and S. Windecker Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients Eur Heart J 29 2008 718 725
21. R.A. Byrne, S. Kufner, K. Tiroch, S. Massberg, K.L. Laugwitz, A. Birkmeier, S. Schulz, and J. Mehilli Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 2009 1489 1494
22. M. Balducelli, P. Ortolani, P. Marzaroli, G. Piovaccari, A. Menozzi, A. Manari, P. Sangiorgio, F. Tarantino, R. Rossi, A. Maresta, S. Tondi, F. Passerini, P. Guastaroba, R. Grilli, and A. Marzocchi Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry Catheter Cardiovasc Interv 75 2009 327 334
23. M.B. Leon, D.E. Kandzari, E.L. Eisenstein, K.J. Anstrom, L. Mauri, D.E. Cutlip, E. Nikolsky, C. OShaughnessy, P.A. Overlie, A.J. Kirtane, B.T. McLaurin, S.L. Solomon, J.S. Jr Douglas, and J.J. Popma Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 2009 1208 1218
24. Y. Onuma, P.W. Serruys, N. Kukreja, S. Veldhof, J. Doostzadeh, S. Cao, and G.W. Stone Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials Eur Heart J 31 2010 1071 1078
25. R. Hoffmann, C. Hamm, C.A. Nienaber, B. Levenson, T. Bonzel, G. Sabin, J. Senges, R. Zahn, U. Tebbe, T. Pfannebecker, H.G. Richardt, S. Schneider, and M. Kelm Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels Coron Artery Dis 18 2007 559 564
26. T. Okabe, J. Lindsay, A.N. Buch, D.H. Steinberg, P. Roy, T.L. Slottow, K. Smith, R. Torguson, Z. Xue, L.F. Satler, K.M. Kent, A.D. Pichard, N.J. Weissman, and R. Waksman Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts Am J Cardiol 102 2008 530 534
27. P.H. van Twisk, J. Daemen, N. Kukreja, R.T. van Domburg, and P.W. Serruys Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts EuroIntervention 4 2008 311 317
28. M.A. Costa, M. Sabate, W.J. van der Giessen, I.P. Kay, P. Cervinka, J.M. Ligthart, P. Serrano, V.L. Coen, P.C. Levendag, and P.W. Serruys Late coronary occlusion after intracoronary brachytherapy Circulation 100 1999 789 792
29. R. Waksman Late thrombosis after radiation Sitting on a time bomb Circulation 100 1999 780 782
30. B.M. Rahel, G.J. Laarman, J.C. Kelder, J.M. ten Berg, and M.J. Suttorp Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study) Am Heart J 157 2009 149 155
31. J. Daemen, H.M. Garcia-Garcia, N. Kukreja, F. Imani, P.P. de Jaegere, G. Sianos, R.T. van Domburg, and P.W. Serruys The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus Eur Heart J 28 2007 26 32
32. M. Menichelli, A. Parma, A. Giulivi, and R. Violini Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI 2 years results) (abstract) Am J Cardiol 100 suppl 2007 210L
33. M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari, D. Barbieri, G. Parrinello, G. Percoco, and R. Ferrari Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study J Am Coll Cardiol 50 2007 138 145
34. P.W. Serruys, J. Daemen, M.C. Morice, B.B. De, A. Colombo, C. Macaya, G. Richardt, J. Fajadet, C. Hamm, K.D. Dawkins, P. Vranckx, M. Bressers, D.R. Van, M. Schuijer, K. Wittebols, M. Pieters, and H.P. Stoll Three-year follow-up of the ARTS-II#sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease EuroIntervention 3 2008 450 459
35. S.J. Park, D.W. Park, Y.H. Kim, S.J. Kang, S.W. Lee, C.W. Lee, K.H. Han, S.W. Park, S.C. Yun, S.G. Lee, S.W. Rha, I.W. Seong, M.H. Jeong, S.H. Hur, N.H. Lee, J. Yoon, J.Y. Yang, B.K. Lee, Y.J. Choi, W.S. Chung, D.S. Lim, S.S. Cheong, K.S. Kim, J.K. Chae, D.Y. Nah, D.S. Jeon, K.B. Seung, J.S. Jang, H.S. Park, and K. Lee Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382